Home World News FDA Approves Gemcitabine Intravesical System for Non-Muscle Invasive Bladder Cancer World News FDA Approves Gemcitabine Intravesical System for Non-Muscle Invasive Bladder Cancer By Ogkologos - September 19, 2025 658 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the Cohort 2 of SunRISe-1 study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR Avelumab Ineffective in Patients with MSS Endometrial Cancer Carrying TP53 Mutation June 5, 2024 No Difference in DFS Between Post-adjuvant Chemotherapy and Placebo In High-Risk... June 22, 2026 5 ways cancer can impact sexual wellbeing May 17, 2023 Adding Avelumab to Preoperative Chemoradiotherapy Provides Promising Anti-Tumour Activity in Locally... July 8, 2021 Load more HOT NEWS Taking Control – Risks vs. Benefits Chemotherapy-Free Regimen of Targeted Agent and Immunotherapeutic Superior to Imatinib and... Higher Risk of Heart Failure Seen in Some Cancers ESMO Welcomes European Parliament (EP) Draft Report on Psychosocial Risks at...
